TTK Healthcare (BOM:507747) EBIT: ₹855 Mil (TTM As of Mar. 2026)


BOM:507747 TTK Healthcare Ltd BOM:507747
72 GF Score
Price ₹911.05
GF Value ₹1,457.02
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is TTK Healthcare EBIT?

TTK Healthcare BOM:507747 -1.54% 72 EBIT is ₹855 Mil as of Mar. 2026. GuruFocus rates BOM:507747 with a GF Score™ of 72/100 and a GF Value™ of ₹1,457.02 (Possible Value Trap). The stock has 2 warning signs investors should review.

TTK Healthcare's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ₹302 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹855 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. TTK Healthcare's annualized ROC % for the quarter that ended in Mar. 2026 was 10.27%. TTK Healthcare's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 90.59%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. TTK Healthcare's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 25.38%.

TTK Healthcare  (BOM:507747) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

TTK Healthcare's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=355.632 * ( 1 - 26.29% )/( (0 + 2552.315)/ 1 )
=262.1363472/2552.315
=10.27 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0 - 0 - ( 0 - max(0, 0 - 0+0))
=0

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=13287.425 - 985.859 - ( 9749.251 - max(0, 2062.346 - 12179.003+9749.251))
=2552.315

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

TTK Healthcare's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=1206.524/( ( (0 + max(0, 0)) + (740.407 + max(591.393, 0)) )/ 1 )
=1206.524/( ( 0 + 1331.8 )/ 1 )
=1206.524/1331.8
=90.59 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0 + 0 + 0)
=0

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1106.631 + 1087.172 + 235.949) - (985.859 + 0 + 852.5)
=591.393

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

TTK Healthcare's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=854.918/3367.968
=25.38 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TTK Healthcare EBIT Related Terms

TTK Healthcare EBIT Historical Data

* Premium members only.

The historical data trend for TTK Healthcare's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TTK Healthcare EBIT Chart

TTK Healthcare Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 280.75 668.75 860.49 1,116.56 854.92

TTK Healthcare Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 226.61 184.23 221.35 147.70 301.63

BOM:507747 vs LLY, JNJ, ABBV: EBIT Comparison

For the Drug Manufacturers - General subindustry, TTK Healthcare's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TTK Healthcare EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, TTK Healthcare's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where TTK Healthcare's EV-to-EBIT falls into.


BOM:507747
72GF Score
TTK Healthcare Ltd BOM:507747
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TTK Healthcare EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹855 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹855 Mil mean?
TTK Healthcare (BOM:507747) has a EBIT of ₹855 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on TTK Healthcare.
Is TTK Healthcare's EBIT too high?
TTK Healthcare's current EBIT is ₹855 Mil. Overall, TTK Healthcare has a GF Score™ of 72/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does TTK Healthcare's EBIT compare to LLY and JNJ?
TTK Healthcare's EBIT of ₹855 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on TTK Healthcare. TTK Healthcare's current EBIT is ₹855 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TTK Healthcare stock overvalued right now?
Based on GuruFocus' analysis, TTK Healthcare (BOM:507747) is currently considered Possible Value Trap. The stock's GF Value™ is ₹1,457.02, compared to a current price of ₹911.05 — trading 37.5% below its estimated fair value. The current EBIT is ₹855 Mil. TTK Healthcare's overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For TTK Healthcare (BOM:507747), the current EBIT is ₹855 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TTK Healthcare (BOM:507747) Overvalued in 2026?

Based on GuruFocus' analysis, TTK Healthcare stock appears to be undervalued. The current stock price of ₹911.05 is trading 37.5% below its estimated GF Value™ of ₹1,457.02. GuruFocus considers TTK Healthcare to be Possible Value Trap.

Key valuation signals for BOM:507747:

  • EBIT: ₹855 Mil
  • GF Value™: ₹1,457.02 vs. price of ₹911.05 (37.5% below fair value)
  • GF Score™: 72/100 with 2 warning signs

No single metric tells the full story. See the BOM:507747 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TTK Healthcare Business Description

Other Exchanges TTKHLTCARE:India
Address No. 6, Cathedral Road, Chennai, TN, IND, 600 086
TTK Healthcare Ltd is an Indian pharmaceutical company. The company's operating segment includes Animal Welfare, Consumer Products, Medical Devices, Protective Devices, Foods Division, and Others. Its Animal Welfare segment includes products for both Human and Veterinary use. The Consumer Products comprises of marketing and distribution of Woodwards's Gripe Water, EVA Range of Cosmetics, Good Home range of Scrubbers, Air Fresheners and others. Protective Devices comprises of manufacturing and marketing of Male Contraceptives and other allied products. It generates maximum revenue from the Pharmaceuticals segment. Geographically, it derives a majority of revenue from India.
72GF Score

Get the complete analysis for BOM:507747

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹911.05
Price
₹1,457.02
GF Value